BY Maria Outze
-
He left Novo to build a new obesity company from scratch: “Ultimately, it feels like the right thing to do.”
It had not been simple for Jacob Jeppesen to finish his VP duty at Novo Nordisk. However the possibility to establish the training course for a brand-new excessive weight business …
-
Novo Nordisk US public affairs veteran to exit company
Steve Albers is tipping down as elderly vice head of state of market gain access to and public events at Novo Nordisk, complying with one more elderly separation in the United Stat…
-
Pfizer is trying to get a priority voucher from Trump
Pfizer was amongst the very first to become part of a rates contract with Trump. However unlike a number of rivals, Pfizer did not obtain a crucial FDA benefit. Chief executive off…
-
Group EVP claims Eli Lilly has changed the US obesity market
“When it comes to commercialization, we have driven the growing importance of consumers,” says group director at Eli Lilly.
-
Zealand Pharma enters new partnership to leverage AI supercomputer technology
With its brand-new AI partnership, Zealand Pharma intends to fast-track the growth of brand-new medications.
-
New executive at Orifarm points to opt-outs as the biggest challenge
Jutta Schnirring-Mayers will certainly make use of her experience in developing item profiles within common medications for a number of worldwide business in her brand-new placemen…
-
Despite chaos in the US, M&A professionals foresee surge in corporate transactions: “We are facing a boom”
Medicinalselskabernes omfattende patentkløfter sætter turbo M&A- markedet, guys kampen om fremtidens lægemidler vil skrue op for priserne i 2026, spår M&A- people.
-
Genmab drops development of important cancer candidate
Genmab’s chief executive officer has actually consistently highlighted cancer cells medicine prospect acasunlimab as a significant sales intend to load the profits void at th…
-
J&J scraps eczema candidate from billion-dollar acquisition
Johnson & Johnson got the dermatitis prospect in 2024 with a USD 1.25 bn procurement. The pharmaceutical business has actually currently chosen to stop additional advancement.
-
The hunt is on for a top executive for a new innovation district
According to talent scout Per Christensen, that is in charge of employment, this will certainly not be a “timeless chief executive officer function.”
